Mcl-1overexpression, which has been reported as an essential mediator of antitumor effects of sorafenib in HCC, resulted in a similar trend of negating the enhancement between GADD45γ and sorafenib (Supplementary Figure S6). The gene discussed is GADD45G; the disease is hepatocellular carcinoma.